JP2005539023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005539023A5 JP2005539023A5 JP2004527531A JP2004527531A JP2005539023A5 JP 2005539023 A5 JP2005539023 A5 JP 2005539023A5 JP 2004527531 A JP2004527531 A JP 2004527531A JP 2004527531 A JP2004527531 A JP 2004527531A JP 2005539023 A5 JP2005539023 A5 JP 2005539023A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hydrocarbyl
- group
- halo
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 53
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 34
- -1 cyano, carboxyl Chemical group 0.000 claims 27
- 125000001475 halogen functional group Chemical group 0.000 claims 19
- 125000002252 acyl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 210000001742 aqueous humor Anatomy 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000004043 oxo group Chemical group O=* 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 150000003180 prostaglandins Chemical class 0.000 claims 10
- 102000003846 Carbonic anhydrases Human genes 0.000 claims 9
- 108090000209 Carbonic anhydrases Proteins 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 206010033799 Paralysis Diseases 0.000 claims 8
- 125000002837 carbocyclic group Chemical group 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 8
- 230000000737 periodic effect Effects 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 206010030113 Oedema Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 229960003933 dorzolamide Drugs 0.000 claims 5
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- UGAMYTZPFRXCOG-PPHPATTJSA-N (4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide;hydrochloride Chemical compound Cl.CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 UGAMYTZPFRXCOG-PPHPATTJSA-N 0.000 claims 4
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 4
- 229960000571 acetazolamide Drugs 0.000 claims 4
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical group CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 208000008445 altitude sickness Diseases 0.000 claims 4
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 4
- 229960000722 brinzolamide Drugs 0.000 claims 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000002934 diuretic Substances 0.000 claims 4
- 230000001882 diuretic effect Effects 0.000 claims 4
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 229960004083 methazolamide Drugs 0.000 claims 4
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000004575 stone Substances 0.000 claims 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 3
- 229960003067 cystine Drugs 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 229940116269 uric acid Drugs 0.000 claims 3
- WTPCCFHCHCMJIT-UHFFFAOYSA-N 1,2,5-oxathiazine Chemical compound O1SC=CN=C1 WTPCCFHCHCMJIT-UHFFFAOYSA-N 0.000 claims 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010030043 Ocular hypertension Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 2
- 229960002576 amiloride Drugs 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 2
- 210000002159 anterior chamber Anatomy 0.000 claims 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229960004064 bumetanide Drugs 0.000 claims 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 229960002155 chlorothiazide Drugs 0.000 claims 2
- 239000000064 cholinergic agonist Substances 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 229960003199 etacrynic acid Drugs 0.000 claims 2
- 229940014142 ethacrynate Drugs 0.000 claims 2
- 229960003883 furosemide Drugs 0.000 claims 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 2
- 229960004569 indapamide Drugs 0.000 claims 2
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims 2
- 229960002817 metolazone Drugs 0.000 claims 2
- 229940054534 ophthalmic solution Drugs 0.000 claims 2
- 239000002997 ophthalmic solution Substances 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 2
- 229960002256 spironolactone Drugs 0.000 claims 2
- 229960001288 triamterene Drugs 0.000 claims 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 1
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- JZTKNVMVUVSGJF-UHFFFAOYSA-N 1,2,3,5-oxatriazole Chemical group C=1N=NON=1 JZTKNVMVUVSGJF-UHFFFAOYSA-N 0.000 claims 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 1
- PPYNEJLGBMVWMC-UHFFFAOYSA-N 1,2,6-oxathiazine Chemical compound O1SC=CC=N1 PPYNEJLGBMVWMC-UHFFFAOYSA-N 0.000 claims 1
- VCZQYTJRWNRPHF-UHFFFAOYSA-N 1,2-dioxin Chemical compound O1OC=CC=C1 VCZQYTJRWNRPHF-UHFFFAOYSA-N 0.000 claims 1
- PCGDBWLKAYKBTN-UHFFFAOYSA-N 1,2-dithiole Chemical group C1SSC=C1 PCGDBWLKAYKBTN-UHFFFAOYSA-N 0.000 claims 1
- FFJBRYXQVYFDEQ-UHFFFAOYSA-N 1,3,2-dioxazole Chemical group N1OC=CO1 FFJBRYXQVYFDEQ-UHFFFAOYSA-N 0.000 claims 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims 1
- IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical group C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 claims 1
- OHOXMCCFSFSRMD-UHFFFAOYSA-N 1,3-oxathiole Chemical group C1OC=CS1 OHOXMCCFSFSRMD-UHFFFAOYSA-N 0.000 claims 1
- ZWEGOVJVJZJDQJ-UHFFFAOYSA-N 1,4,2-dioxazole Chemical group C1OC=NO1 ZWEGOVJVJZJDQJ-UHFFFAOYSA-N 0.000 claims 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical group N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 claims 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical group C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 claims 1
- HPYLZSUEFFQHRS-UHFFFAOYSA-N 2h-1,2,4-oxadiazine Chemical compound N1OC=CN=C1 HPYLZSUEFFQHRS-UHFFFAOYSA-N 0.000 claims 1
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 claims 1
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims 1
- ACVSHQGHCWUJFU-UHFFFAOYSA-N 2h-imidazole Chemical group C1N=CC=N1 ACVSHQGHCWUJFU-UHFFFAOYSA-N 0.000 claims 1
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical group C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 claims 1
- QLXDONQYFHWXFW-UHFFFAOYSA-N 3h-1,2,4-dioxazole Chemical group C1OOC=N1 QLXDONQYFHWXFW-UHFFFAOYSA-N 0.000 claims 1
- RELAJOWOFXGXHI-UHFFFAOYSA-N 3h-oxathiole Chemical group C1SOC=C1 RELAJOWOFXGXHI-UHFFFAOYSA-N 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 claims 1
- UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 claims 1
- UOSQFVCDJBZRKS-UHFFFAOYSA-N 4h-1,4-oxazine Chemical compound N1C=COC=C1 UOSQFVCDJBZRKS-UHFFFAOYSA-N 0.000 claims 1
- BMRPOOWUTVUBRI-UHFFFAOYSA-N 4h-oxazine Chemical compound C1C=CON=C1 BMRPOOWUTVUBRI-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- UQDOOWVOKCUFNC-UHFFFAOYSA-N 5h-1,2,5-oxathiazole Chemical group N1OSC=C1 UQDOOWVOKCUFNC-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- GMLMFZXBPRIXPK-UHFFFAOYSA-N 6h-1,3-oxazine Chemical compound C1OC=NC=C1 GMLMFZXBPRIXPK-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000002682 Hyperkalemia Diseases 0.000 claims 1
- 208000019025 Hypokalemia Diseases 0.000 claims 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims 1
- 108010044467 Isoenzymes Proteins 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010027423 Metabolic alkalosis Diseases 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 claims 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 claims 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 201000001326 acute closed-angle glaucoma Diseases 0.000 claims 1
- 230000004509 aqueous humor production Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229960004324 betaxolol Drugs 0.000 claims 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims 1
- 229960002470 bimatoprost Drugs 0.000 claims 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims 1
- 229960004484 carbachol Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960001222 carteolol Drugs 0.000 claims 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- IIDLNHSEMPPGKB-UHFFFAOYSA-N cyclopentene furan Chemical group O1C=CC=C1.C1=CCCC1 IIDLNHSEMPPGKB-UHFFFAOYSA-N 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 claims 1
- 229960000966 dipivefrine Drugs 0.000 claims 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 claims 1
- 229960002506 dorzolamide hydrochloride Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical group C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 229960000831 levobunolol Drugs 0.000 claims 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims 1
- 229960002704 metipranolol Drugs 0.000 claims 1
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical group C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960001697 physostigmine Drugs 0.000 claims 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
- 229960001416 pilocarpine Drugs 0.000 claims 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 claims 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 claims 1
- 208000024896 potassium deficiency disease Diseases 0.000 claims 1
- 208000001381 pseudotumor cerebri Diseases 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229930192474 thiophene Chemical group 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229960005221 timolol maleate Drugs 0.000 claims 1
- 229960002368 travoprost Drugs 0.000 claims 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 1
- 229960004317 unoprostone Drugs 0.000 claims 1
- UJLPVGLFJFFLCR-UHFFFAOYSA-N NS(c(cc1)ccc1-[n]1nccc1)(=O)=O Chemical compound NS(c(cc1)ccc1-[n]1nccc1)(=O)=O UJLPVGLFJFFLCR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/213,793 US20030100594A1 (en) | 2001-08-10 | 2002-08-07 | Carbonic anhydrase inhibitor |
| PCT/US2003/004494 WO2004014352A2 (en) | 2002-08-07 | 2003-02-14 | Methods for treating carbonic anhydrase mediated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005539023A JP2005539023A (ja) | 2005-12-22 |
| JP2005539023A5 true JP2005539023A5 (US06815460-20041109-C00007.png) | 2006-03-30 |
Family
ID=31714232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527530A Withdrawn JP2005539022A (ja) | 2002-08-07 | 2003-02-14 | 悪性腫瘍の治療のためのシクロオキシゲナーゼ−２選択的阻害剤及びカルボニックアンヒドラーゼ阻害剤の組成物 |
| JP2004527531A Withdrawn JP2005539023A (ja) | 2002-08-07 | 2003-02-14 | 炭酸脱水酵素媒介疾患の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527530A Withdrawn JP2005539022A (ja) | 2002-08-07 | 2003-02-14 | 悪性腫瘍の治療のためのシクロオキシゲナーゼ−２選択的阻害剤及びカルボニックアンヒドラーゼ阻害剤の組成物 |
Country Status (12)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| DE10035227A1 (de) * | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| US20100135980A1 (en) * | 2000-10-16 | 2010-06-03 | Rodriguez Victorio C | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy |
| US20030220376A1 (en) * | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| GEP20094664B (en) | 2003-05-22 | 2009-04-10 | Nerviano Medical Sciences Srl | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| WO2005079781A1 (en) * | 2004-02-25 | 2005-09-01 | La Trobe University | Therapeutic and/or prophylactic method |
| WO2005094815A1 (en) * | 2004-03-30 | 2005-10-13 | Amorepacific Corporation | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| CA2609185A1 (en) | 2005-05-20 | 2006-11-30 | Ahmed F. Abdel-Magid | Process for preparation of sulfamide derivatives |
| JP4872076B2 (ja) * | 2005-09-15 | 2012-02-08 | 国立大学法人 長崎大学 | 硝子体可視化剤 |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| EP2026790A2 (en) | 2006-05-19 | 2009-02-25 | Janssen Pharmaceutica, N.V. | Co-therapy for the treatment of epilepsy and related disorders |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| WO2008075148A2 (en) * | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Tricyclic inhibitors of carbonic anhydrase |
| RU2498798C2 (ru) * | 2008-01-09 | 2013-11-20 | Моликьюлар Инсайт Фармасьютикалз, Инк. | Ингибиторы карбоангидразы iх |
| MX2011000090A (es) | 2008-06-23 | 2011-03-02 | Janssen Pharmaceutica Nv | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida. |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| WO2010065906A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
| EP2706057B1 (en) | 2008-12-05 | 2016-04-20 | Molecular Insight Pharmaceuticals, Inc. | Bis(imidazolyl)compounds and radionuclide complexes |
| AU2009322164B2 (en) | 2008-12-05 | 2014-12-18 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
| CN102428086B (zh) * | 2009-04-29 | 2014-08-20 | 内尔维阿诺医学科学有限公司 | Cdk抑制剂的盐类 |
| AU2010260195B2 (en) | 2009-06-15 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
| WO2011047796A1 (en) * | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| US9125899B1 (en) | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
| JP5918227B2 (ja) * | 2010-07-09 | 2016-05-18 | ウェリケム・バイオテック・インコーポレイテッドＷｅｌｉｃｈｅｍ Ｂｉｏｔｅｃｈ Ｉｎｃ． | 転移性腫瘍の生長抑制のための新規なスルホンアミド化合物 |
| EP2614065B1 (en) * | 2010-12-17 | 2017-04-19 | Nerviano Medical Sciences S.r.l. | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| CN102351793B (zh) * | 2011-08-30 | 2013-11-06 | 江苏正大清江制药有限公司 | 4-[3-(4-甲基苯基)-5-(三氟甲基)-1-氢-吡唑-1-基]苯磺酰胺的直接合成方法 |
| BR112014006940A2 (pt) | 2011-09-23 | 2017-04-04 | Bayer Ip Gmbh | uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas |
| AU2013207486A1 (en) | 2012-01-06 | 2014-08-21 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
| ES2648096T3 (es) | 2013-01-14 | 2017-12-28 | Molecular Insight Pharmaceuticals, Inc. | Radiofármacos a base de triazina y agentes de radioformación de imágenes |
| US10391119B2 (en) * | 2015-12-22 | 2019-08-27 | Nof Corporation | Lacrimal oily layer stabilizer and eye drops comprising same |
| WO2018211474A1 (en) | 2017-05-19 | 2018-11-22 | Trudell Medical International | Positive expiratory pressure device |
| USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
| USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
| USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
| CN109557309B (zh) * | 2018-12-04 | 2021-09-10 | 九江学院附属医院 | 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用 |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| CN115607567A (zh) * | 2022-09-28 | 2023-01-17 | 长春工业大学 | 一种环保型改善心肌缺血的血液透析液 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1582619A (en) * | 1977-05-14 | 1981-01-14 | Centrala Ind Medicamente | Medicinal compositions for the treatment of gastritis gastro-duodenitis and duodenal ulcers |
| US5157044A (en) * | 1983-02-04 | 1992-10-20 | University Of Iowa Research Foundation | Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors |
| US5095026A (en) * | 1983-02-04 | 1992-03-10 | University Of Iowa Research Foundation | Prodrugs of carbonic anhydrase inhibitors |
| US4911920A (en) * | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| AU665341B2 (en) * | 1990-12-18 | 1996-01-04 | Wellcome Foundation Limited, The | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| AU653279B2 (en) * | 1991-12-30 | 1994-09-22 | Sanofi | Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US6090834A (en) * | 1993-05-21 | 2000-07-18 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
| KR100229343B1 (ko) * | 1993-11-30 | 1999-11-01 | 윌리암스 로저 에이 | 염증치료용 치환 피라졸일벤젠술폰아미드 |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| AU699593B2 (en) * | 1995-02-13 | 1998-12-10 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
| DE19600721A1 (de) * | 1996-01-12 | 1997-07-17 | Hoechst Ag | Verwendung von Inhibitoren des Carboanhydratase (CAH) zum Herstellen eines Medikaments zur Behandlung von Krebs |
| TR199801665T2 (xx) * | 1996-02-26 | 1998-12-21 | Advanced Research & Technology Institute | Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�. |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| CA2372912C (en) * | 1997-10-14 | 2008-12-02 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| US5972684A (en) * | 1997-11-25 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Carbonic anhydrase VIII |
| ES2140354B1 (es) * | 1998-08-03 | 2000-11-01 | S A L V A T Lab Sa | Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2. |
| WO2000018741A2 (en) * | 1998-09-30 | 2000-04-06 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds as cox-2 inhibitors |
| SE9803761D0 (sv) * | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
| ATE342054T1 (de) * | 1999-04-14 | 2006-11-15 | Dana Farber Cancer Inst Inc | Verfahren und zusammansetzung zur behandlung von krebs |
| US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
| AU2584001A (en) * | 2000-01-03 | 2001-07-16 | Pharmacia Corporation | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders |
| US20010046982A1 (en) * | 2000-02-01 | 2001-11-29 | Maxey Kirk M. | Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension |
| US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| JP2002179657A (ja) * | 2000-05-26 | 2002-06-26 | Japan Tobacco Inc | ５−（４−アミノスルホニル−３−フルオロフェニル）−４−シクロヘキシル−２−メチルオキサゾールの結晶多形 |
| US20020009421A1 (en) * | 2000-06-01 | 2002-01-24 | Wilder Karol J. | Therapy following skin injury from exposure to ultraviolet radiation |
| US20020128267A1 (en) * | 2000-07-13 | 2002-09-12 | Rebanta Bandyopadhyay | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| DE60110087T2 (de) * | 2000-08-11 | 2005-09-29 | Einar Stefansson | Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern |
| SE0004229D0 (sv) * | 2000-11-17 | 2000-11-17 | Aga Ab | Inhalation of nitric oxide |
| WO2003013655A2 (en) * | 2001-08-10 | 2003-02-20 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
-
2002
- 2002-08-07 US US10/213,793 patent/US20030100594A1/en not_active Abandoned
-
2003
- 2003-02-14 BR BR0313282-0A patent/BR0313282A/pt not_active IP Right Cessation
- 2003-02-14 CA CA002495502A patent/CA2495502A1/en not_active Abandoned
- 2003-02-14 CA CA002495516A patent/CA2495516A1/en not_active Abandoned
- 2003-02-14 WO PCT/US2003/004494 patent/WO2004014352A2/en not_active Application Discontinuation
- 2003-02-14 AU AU2003225571A patent/AU2003225571A1/en not_active Abandoned
- 2003-02-14 WO PCT/US2003/004469 patent/WO2004014430A1/en not_active Application Discontinuation
- 2003-02-14 MX MXPA05001497A patent/MXPA05001497A/es not_active Application Discontinuation
- 2003-02-14 MX MXPA05001496A patent/MXPA05001496A/es not_active Application Discontinuation
- 2003-02-14 AU AU2003213062A patent/AU2003213062A1/en not_active Abandoned
- 2003-02-14 JP JP2004527530A patent/JP2005539022A/ja not_active Withdrawn
- 2003-02-14 PL PL03374994A patent/PL374994A1/xx unknown
- 2003-02-14 EP EP03709105A patent/EP1526895A2/en not_active Withdrawn
- 2003-02-14 BR BR0313299-4A patent/BR0313299A/pt not_active IP Right Cessation
- 2003-02-14 KR KR1020057002072A patent/KR20050056189A/ko not_active Application Discontinuation
- 2003-02-14 JP JP2004527531A patent/JP2005539023A/ja not_active Withdrawn
- 2003-02-14 EP EP03784730A patent/EP1526869A1/en not_active Withdrawn
- 2003-02-14 CN CNA038218801A patent/CN1681557A/zh active Pending
-
2004
- 2004-04-19 US US10/827,075 patent/US20040198781A1/en not_active Abandoned
-
2005
- 2005-02-03 IL IL16668505A patent/IL166685A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005539023A5 (US06815460-20041109-C00007.png) | ||
| AU745797B2 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
| ES2262156T3 (es) | Composicion que comprende un inhibidor de la ciclooxigenasa 2 y un inhibidor de la leucotrieno a4 hidrolasa. | |
| US6136839A (en) | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | |
| US20020107276A1 (en) | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist | |
| EP0888127B1 (en) | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors | |
| EP0880362B1 (en) | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b 4 receptor antagonist | |
| ES2252448T3 (es) | Composicion parenteral reconstituible que contiene un inhibidor de la cox-2. | |
| CA2495502A1 (en) | Methods for treating carbonic anhydrase mediated disorders | |
| EP0880363B1 (en) | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor | |
| JP2004526765A5 (US06815460-20041109-C00007.png) | ||
| JP2008297308A (ja) | 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用 | |
| US20030157061A1 (en) | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor | |
| RU2004121147A (ru) | Применение ингибиторов сох-2 в сочетании с противовирусными агентами для лечения инфекции вируса папилломы | |
| US20030220376A1 (en) | Methods for treating carbonic anhydrase mediated disorders | |
| JP2005501850A5 (US06815460-20041109-C00007.png) | ||
| JP2005507871A5 (US06815460-20041109-C00007.png) | ||
| CA2414674A1 (en) | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders | |
| US20020035156A1 (en) | Combination therapy in the prevention of cardiovascular disorders | |
| JP2005501083A5 (US06815460-20041109-C00007.png) | ||
| JP2008533109A (ja) | 利尿を促進するための複合治療 | |
| JP2001521889A5 (US06815460-20041109-C00007.png) | ||
| JP2005535657A5 (US06815460-20041109-C00007.png) |
